Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of one systematic review(s)/meta-analysis(es). ^[1]
• Untreated Peripheral T-cell Lymphoma (PTCL) Patients: High-dose chemotherapy (HDAC) inhibitors demonstrated a pooled complete response (CR) rate of 44% (95% CI (confidence interval), 39-48%) in untreated PTCL patients.
• Relapsed/Refractory (R/R) PTCL Patients: The pooled CR rate for HDAC inhibitors in R/R PTCL was 14% (95% CI, 11-16%), with combination therapies showing improved efficacy over monotherapy (P = 0.02).
• Subtype-Specific Response: In R/R Angioimmunoblastic T-cell Lymphoma patients, the pooled overall response rate (ORR) was higher at 44% (95% CI, 35-53%) compared to other PTCL subtypes.
• Adverse Events in PTCL Treatment with HDAC Inhibitors: Thrombocytopenia was the most commonly reported hematological adverse event, while nausea was the most frequent non-hematological adverse event.
• Safety Comparisons: The studies did not provide specific safety comparisons between belinostat and other HDAC inhibitors (romidepsin and chidamide), nor did they indicate unique safety concerns specific to subgroups or populations. There is no population types or subgroups information available in the reviewed studies.